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A Meta-Analysis of 16 Randomized Trials of
Sirolimus-Eluting Stents Versus Paclitaxel-Eluting
Stents in Patients With Coronary Artery Disease
Albert Schömig, MD,* Alban Dibra, MD,* Stephan Windecker, MD,† Julinda Mehilli, MD,*
José Sua´rez de Lezo, MD,‡ Christoph Kaiser, MD,§ Seung-Jung Park, MD, Jean-Jacque Goy, MD,††
Jae-Hwan Lee, MD,¶ Emilio Di Lorenzo, MD,# Jinjin Wu, MD,* Peter Jüni, MD,**
Matthias E. Pfisterer, MD,§ Bernhard Meier, MD,† Adnan Kastrati, MD*
Munich, Germany; Bern, Basel, and Lausanne, Switzerland; Córdoba, Spain; Seoul and Daejeon, Korea;
and Avellino, Italy
Objectives Our purpose was to make a synthesis of the available evidence on the relative efficacy and safety of 2 drug-
eluting stents (DES)—sirolimus-eluting stent (SES) and paclitaxel-eluting stent (PES)—in patients with coronary
artery disease.
Background It is not known whether there are differences in late outcomes between the 2most commonly used DES: SES and PES.
Methods Sixteen randomized trials of SES versus PES with a total number of 8,695 patients were included in this meta-analysis. A
full set of individual outcome data from 5,562 patients was also available. Mean follow-up period ranged from 9 to 37
months. The primary efficacy end point was the need for reintervention (target lesion revascularization). The primary
safety end point was stent thrombosis. Secondary end points were death and recurrent myocardial infarction (MI).
Results No significant heterogeneity was found across trials. Compared with PES, SES significantly reduced the risk of
reintervention (hazard ratio [HR] 0.74; 95% confidence interval [CI] 0.63 to 0.87, p  0.001) and stent thrombo-
sis (HR 0.66; 95% CI 0.46 to 0.94, p  0.02) without significantly impacting on the risk of death (HR 0.92; 95%
CI 0.74 to 1.13, p  0.43) or MI (HR 0.84; 95% CI 0.69 to 1.03, p  0.10).
Conclusions Sirolimus-eluting stents are superior to PES in terms of a significant reduction of the risk of reintervention and
stent thrombosis. The risk of death was not significantly different between the 2 DES, but there was a trend to-
ward a higher risk of MI with PES, especially after the first year from the procedure. (J Am Coll Cardiol 2007;
50:1373–80) © 2007 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.06.047t
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Grug-eluting stents (DES) have largely resolved the prob-
em of restenosis, the major limitation of plain balloon
ngioplasty and bare-metal stenting (1). While several DES
latforms have been evaluated in the setting of randomized
tudies and used in clinical practice, most of the accumu-
ated evidence is related to sirolimus-eluting stents (SES)
nd paclitaxel-eluting stents (PES) (2). These devices are
he only DES approved by the U.S. Food and Drug
dministration (3).
rom the *Deutsches Herzzentrum, Technische Universität, Munich, Germany; †De-
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edicine, University Hospital Bern, Bern, Switzerland; and the ††Service of Cardiology,
linique Cecil, Lausanne, Switzerland. Dr. Schömig reports receiving unrestricted
rant support for the Department of Cardiology he chairs from Amersham/General
lectric, Bayerische Forschungsstiftung, Bristol-Myers Squibb, Cordis, Cryocath, aThe DES have been linked to a higher risk of late stent
hrombosis compared with bare-metal stents (4,5), a phe-
omenon that was not identified in the initial trials with
See page 1381
hort- to midterm follow-up (6). Furthermore, several
tudies suggested that SES and PES may be associated with
ncreased mortality and myocardial infarction (MI) rates
uidant, Medtronic, Nycomed, and Schering; Dr. Windecker has received lecture fees
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SES Versus PES October 2, 2007:1373–80(4,7–9). Serious concerns have
been raised regarding the long-
term safety of these DES (10–
12), although more comprehen-
sive, patient-based meta-analyses
do not justify these concerns
(13,14). The SES and PES differ
importantly with respect to poly-
mer coating and antiproliferative
drugs, which may impact on the
risk of late adverse events associ-
ated with these devices. Recently,
he results of 2 meta-analyses suggested that the risk of late
hrombosis or death might be different between SES and
ES (4,9). However, the difference has been implied by
ndirect comparisons from trials comparing SES and PES
ith bare-metal stents separately (4,9). Thus, it remains
ncertain whether there are any differences between SES
nd PES with regard to their long-term safety profile.
otwithstanding, a prior meta-analysis including 6 trials
ith 3,669 patients followed-up for up to 1 year has shown
hat SES are superior to PES in reducing the risk of
estenosis (15). Whether the benefit of the SES is main-
ained beyond this period also remains unknown.
Direct comparison meta-analysis of randomized trials has
he potential to increase power and improve precision of
reatment effects (16). Availability of individual patient data
s the “gold standard” to analyze time-to-event or survival
ata (17). Therefore, we performed a comprehensive meta-
nalysis with a large use of individual patient data from all
linical trials that have evaluated the long-term outcomes
fter coronary implantation of SES and PES.
ethods
linical trial selection. Randomized head-to-head trials
f SES (Cypher, Cordis, Johnson & Johnson, Miami Lakes,
lorida) and PES (TAXUS, Boston Scientific Corp,
atick, Massachusetts) in patients with coronary artery
isease were identified through searches of the PubMed
atabase, U.S. National Institute of Health, Cochrane
entral Register of Controlled Trials, and the proceedings
f the American Heart Association, American College of
ardiology, and European Society of Cardiology. Internet-
ased sources of information on the results of clinical trials
n cardiology were also searched. Other data sources in-
luded reference lists of retrieved articles and pertinent
eviews and editorials from leading medical journals. The
ast search was performed in April 2007.
Sixteen randomized clinical trials were included in this
eta-analysis (18–33). The main characteristics of these
rials are displayed in Table 1 and their definitions of events
n Table 2.
utcome variables. The primary efficacy end point of this
eta-analysis was the need for reintervention (target lesion
Abbreviations
and Acronyms
CI  confidence interval
DES  drug-eluting stent(s)
HR  hazard ratio
MI  myocardial infarction
PES  paclitaxel-eluting
stent(s)
SES  sirolimus-eluting
stent(s)evascularization). The primary safety end point of this seta-analysis was stent thrombosis. Secondary end points
ere death and recurrent MI. All trials reported blind
djudication of adverse events made by the same events
ommittee throughout the follow-up period. Event defini-
ions for each trial are listed in Table 2.
ata collection and assessment of quality. Principal in-
estigators or sponsors of each eligible trial were asked to
omplete electronic datasheets encompassing the following
ata for each individual patient: date of randomization;
reatment assigned by randomization; death, MI, reinter-
ention, stent thrombosis, and their respective date of
ccurrence; and date of last follow-up. Data for surviving
atients were censored at the date of last contact. The
rincipal investigators from 11 of the 16 randomized trials
greed to provide individual patient data (18,20,21,23–
6,28–30,32). Summary outcome data of the remaining 5
rials were extracted from the respective publications or
resentations or obtained directly from the investigators
19,22,27,31,33).
The following methodological criteria were evaluated for
ll included trials: adequacy of allocation concealment,
erformance of the analysis according to the intention-to-
reat principle, and blind assessment of the outcomes of
nterest. No summary score was used to identify low or
igh quality trials; we did not perform weighting by
uality scores as this practice has not been recommended
y some (34 –36).
tatistical analysis. Treatment effects, expressed as hazard
atios (HRs) or relative risks (for trials from which no
ndividual patient data were available) for SES and PES,
ere first estimated for each trial and then combined using
tandard meta-analytic methods. Survival analyses were
erformed for each trial using the Mantel-Cox method,
hich is not based on the proportional hazards assumption;
he log-rank test was used to calculate HRs with 95%
onfidence intervals (CIs). Trials in which the event of
nterest was not observed in any of the treatment groups
ere not included in the analysis of that event. For trials in
hich only one of the treatment groups had no events of
nterest, the treatment effect estimate and its standard error
ere approximated from 2  2 contingency tables after
dding 0.5 to each cell (37). We used the Cochran test to
ssess heterogeneity across trials. Also, we calculated the I2
tatistic to measure the consistency between trials with
alues of 25%, 50%, and 75% representing low, moderate,
nd high degrees of heterogeneity, respectively (38). The
Rs from individual trials were pooled using both the fixed
ffects Mantel-Haenszel model (39) and the random effects
erSimonian and Laird model (40). If no heterogeneity is
resent, both models yield similar results. Herein, we report
he results from the random-effects model. All p values are
-sided. Statistical significance was assumed for p  0.05.
tatistical analysis was performed using the Stata software,
ersion 9.2 (Stata Corp., College Station, Texas). Explor-
tory survival curves, which are presented as simple, non-
tratified Kaplan-Meier curves across all trials, are con-
s
S
R
A
w
t
I
i
2
t
1
(
n
p
w
t
p
g
y
t
d
s
i
(
f
w
(
t
t
M
B
R
S
P
P
P
L trial; TA
W
1375JACC Vol. 50, No. 14, 2007 Schömig et al.
October 2, 2007:1373–80 SES Versus PEStructed using S-Plus software version 4.5 (Insightful Corp.,
eattle, Washington).
esults
total of 16 randomized trials including 8,695 patients
ere analyzed (Table 1). The patients were representative of
he whole clinical spectrum of coronary artery disease.
ndividual patient data were available from 11 trials includ-
ng 5,562 patients who were followed up for a median of
4.3 months (25th, 75th percentiles: 18.4, 28.7 months) in
he SES group and 24.3 months (25th, 75th percentiles:
8.3, 28.5 months) in the PES group (p  0.51)
18,20,21,23–26,28–30,32).
Reintervention, the primary efficacy end point, was
eeded in 295 patients in the SES group versus 380
ain Characteristics of the Trials Included in the Meta-Analysis
Table 1 Main Characteristics of the Trials Included in the Meta
Study
No. of
Patients
Mean
Age (yrs) Patient Profile
BASKET (18) 545 64 Unselected patients
Cervinka et al. (19) 70 56 Complex lesions
and patients
CORPAL (20) 652 61 Unselected patients
Di Lorenzo et al. (21) 180 64 Acute MI
Han et al. (22) 416 NA Multivessel disease
ISAR-DESIRE (23) 200 64 In-stent restenosis
ISAR-DIABETES (24) 250 68 Diabetic patients
ISAR-SMART 3 (25) 360 67 Small vessels,
nondiabetic
patients
LONG DES II (26) 500 61 Long lesions
Petronio et al. (27) 100 63 Complex lesions
PROSIT (28) 308 62 Acute MI
REALITY (29) 1,353 63 Relatively
unselected
patients
SIRTAX (30) 1,012 62 Unselected patients
SORT OUT II (31) 2,098 64 Unselected patients
TAXI (32) 202 64 Unselected patients
Zhang et al. (33) 449 64 Unselected patients
ASKET Basel Stent Kosten Effektivitäts Trial; CORPAL Drug-Eluting Stents for Complex Lesions
esults: Drug-Eluting Stents for In-Stent Restenosis trial; ISAR-DIABETES  Intracoronary Stenti
irolimus-Eluting Stents trial; ISAR-SMART 3 Drug-Eluting Stenting to Abrogate Restenosis in Sm
aclitaxel-Eluting Stent in the Treatment of Long Native Coronary Lesions trial; MI  myocardial
aclitaxel-Eluting Stents for the Treatment of Acute ST-Elevation Myocardial Infarction; REALITY
aclitaxel-Eluting Stent Systems trial; SES sirolimus-eluting stent; SIRTAX Sirolimus-Eluting Ve
arge-Scale, Randomized Trial of Paclitaxel- and Sirolimus-Eluting Stents in “Real-World” Lesions
orld of Interventional Cardiology trial.atients in the PES group. Allocation to the SES group as associated with a hazard ratio (HR) for reinterven-
ion of 0.74 (95% confidence interval [CI] 0.63 to 0.87,
 0.001) (Fig. 1A). There was no significant hetero-
eneity across trials (p  0.39). The sensitivity analysis
ielded HRs that ranged from 0.69 (95% CI 0.59 to 0.82)
o 0.78 (95% CI 0.66 to 0.92) and were not significantly
ifferent from the overall HR (p  0.58). There was no
ignificant interaction between the treatment effect and
nclusion of follow-up angiography in the study protocol
p  0.10). When the analysis was confined to the trials
or which individual patient data were available, SES
ere associated with a HR for reintervention of 0.72
95% CI 0.61 to 0.86, p  0.001). Within the first year,
he HR was 0.70 (95% CI 0.57 to 0.85, p  0.001); after
he first year, the HR was 0.79 (95% CI 0.58 to 1.09, p
lysis
Primary End Point
Protocol-
Mandated
Follow-Up
Angiography
Minimal
Length of
Thienopyridine
Therapy in the
SES/PES
Groups
(Months)
Mean
Length of
Follow-Up
(Months)
t-effectiveness based
n the composite of
eath, MI, or
intervention
No 6/6 18
intima volume in
travascular ultrasound
ssessment
Yes 6/6 24
iographic restenosis
nd clinical events
Yes 12/12 31
th, MI, or reintervention No 6/6 12
th, MI, or reintervention No 9/9 20
iographic restenosis Yes 6/6 34
iographic late loss Yes 6/6 32
iographic late loss Yes 6/6 34
iographic restenosis Yes 6/6 13
intimal area in
travascular ultrasound
ssessment
Yes 6/6 36
diac death, reinfarction,
tent thrombosis, or
rget lesion
vascularization
Yes 6/6 26
iographic restenosis Yes 2/6 24
th, MI, or reintervention Yes 12/12 24
th, MI, or reintervention No 9/9 9
th, MI, or reintervention No 12/12 37
th, MI, or reintervention No 9/12 12
mized Rapamycin Versus Paclitaxel trial; ISAR-DESIRE Intracoronary Stenting and Angiographic
Angiographic Results: Do Diabetic Patients Derive Similar Benefit From Paclitaxel-Eluting and
ries trial; LONG DES II Randomized Comparison of the Efficacy of Sirolimus-Eluting Stent Versus
on; PES  paclitaxel-eluting stent; PROSIT  Prospective Randomized Trial of Sirolimus- versus
spective, Randomized, Multi-Center Comparison of the Cypher Sirolimus-Eluting and the Taxus
clitaxel-Eluting Stents for Coronary Revascularization trial; SORT OUT II Prospective, Multicenter,
XI  Prospective Randomized Comparison Between Paclitaxel and Sirolimus Stents in the Real-Ana
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SES Versus PES October 2, 2007:1373–80eintervention: the 30-month probability of reinterven-
ion was 9.5% in the SES group and 12.7% in the PES
roup.
Stent thrombosis, the primary safety end point, was ob-
erved in 53 patients in the SES group versus 82 patients in the
nd Point Definitions in Each Trial Included in the Meta-Analysis
Table 2 End Point Definitions in Each Trial Included in the Met
Study MI
BASKET (18) Typical chest pain with either typical rise
of cardiac enzymes or new
pathological Q waves/ST-T-wave
changes on ECG
Intervention
in the sam
treated
Cervinka et al. (19) Either pathological Q waves on ECG
or an increase in cardiac enzymes
3 times the upper normal level
Any CABG o
to angiog
of sympto
CORPAL (20) Either pathological Q waves on ECG
or an increase in cardiac enzymes
3 times the upper normal level
Any CABG o
to angiog
of sympto
Di Lorenzo et al. (21) Typical ECG changes and increase of
CK-MB or troponin
Any CABG o
presence
ischemia
Han et al. (22) ECG changes and increase in cardiac
enzymes
PCI due to a
ISAR-DESIRE (23) Either pathological Q waves on ECG
or an increase in cardiac enzymes
3 times the upper normal level
Any CABG o
to angiog
of sympto
ISAR-DIABETES (24) Either pathological Q waves on ECG
or an increase in cardiac enzymes
3 times the upper normal level
Any CABG o
to angiog
of sympto
ISAR-SMART 3 (25) Either pathological Q waves on ECG
or an increase in cardiac enzymes
3 times the upper normal level
Any CABG o
to angiog
of sympto
LONG DES II (26) Either pathological Q waves on ECG
or an increase in cardiac enzymes
3 times the upper normal level
Any CABG o
to angiog
of sympto
due to se
stenosis)
Petronio et al. (27) ECG changes and increase in cardiac
enzymes
PCI due to a
PROSIT (28) New electrocardiographic changes
in association with a re-elevation
of CK-MB
Any CABG o
to angiog
of sympto
due to se
stenosis)
REALITY (29) Either pathological Q waves on ECG
or an increase in cardiac enzymes
2 times the upper normal level
Any CABG o
to angiog
of sympto
due to se
stenosis)
SIRTAX (30) Either pathological Q waves on ECG
or an increase in cardiac enzymes
2 times the upper normal level
Any CABG o
to angiog
of sympto
due to se
stenosis)
SORT OUT II (31) ECG changes and increase in cardiac
enzymes
Any CABG o
to angiog
of sympto
TAXI (32) Either pathological Q waves on ECG
or an increase in cardiac enzymes
2 times the upper normal level
Any CABG o
to angiog
of sympto
Zhang et al. (33) ECG changes and increase in cardiac
enzymes
PCI due to a
ABG  aorto-coronary bypass surgery; CK-MB  creatine kinase-MB; ECG  electrocardiogram;ES group. Allocation to the SES group was associated with HHR for stent thrombosis of 0.66 (95% CI 0.46 to 0.94, p 
.02) (Fig. 2A). There was no significant heterogeneity across
rials (p  0.93). The sensitivity analysis yielded HRs that
anged from 0.55 (95% CI 0.36 to 0.84) to 0.75 (95% CI 0.51
o 1.09) and were not significantly different from the overall
lysis
intervention Stent Thrombosis
r CABG) driven by a lesion
cardial vessel as initially
Angiographic evidence in the presence of an acute
ischemic clinical event
arget vessel or a PCI due
restenosis in the presence
signs of ischemia
Angiographic evidence
arget vessel or a PCI due
restenosis in the presence
signs of ischemia
Angiographic evidence
f the target vessel in the
ptoms or signs of
Angiographically documented thrombus within
the stent associated to typical chest pain and
ST-segment modification
raphic restenosis Angiographic evidence in the presence of an acute
coronary syndrome
arget vessel or a PCI due
restenosis in the presence
signs of ischemia
Angiographic evidence in the presence of an acute
coronary syndrome
arget vessel or a PCI due
restenosis in the presence
signs of ischemia
Angiographic evidence in the presence of an acute
coronary syndrome
arget vessel or a PCI due
restenosis in the presence
signs of ischemia
Angiographic evidence in the presence of an acute
coronary syndrome
arget vessel or a PCI due
restenosis in the presence
signs of ischemia or only
stenosis (70% diameter
Angiographic evidence in the presence of an acute
ischemic event
raphic restenosis Angiographic evidence in the presence of an acute
coronary syndrome
arget vessel or a PCI due
restenosis in the presence
signs of ischemia or only
stenosis (70% diameter
Angiographic documentation of stent occlusion
with or without the presence of thrombus
associated with an acute ischemic event,
unexplained sudden death, or target vessel MI
without angiographic confirmation of
thrombosis or other identified culprit lesion
arget vessel or a PCI due
restenosis in the presence
signs of ischemia or only
stenosis (70% diameter
Early: a 30-day composite of death, Q-wave MI,
or abrupt vessel closure requiring
revascularization. Late: MI attributable to the
target vessel with angiographic documentation
of thrombus or total occlusion at the target site
more than 30 days after the index procedure
arget vessel or a PCI due
restenosis in the presence
signs of ischemia or only
stenosis (70% diameter
An acute coronary syndrome with angiographic
documentation of either occlusion of the target
lesion or thrombus within the previously stented
segment
arget vessel or a PCI due
restenosis in the presence
signs of ischemia
Definite: angiographically proven
arget vessel or a PCI due
restenosis in the presence
signs of ischemia
Angiographic evidence
raphic restenosis Angiographic evidence in the presence of an acute
coronary syndrome
ercutaneous coronary intervention; other abbreviations as in Table 1.a-Ana
Re
(PCI o
e epi
f the t
raphic
ms or
f the t
raphic
ms or
r PCI o
of sym
ngiog
f the t
raphic
ms or
f the t
raphic
ms or
f the t
raphic
ms or
f the t
raphic
ms or
vere re
ngiog
f the t
raphic
ms or
vere re
f the t
raphic
ms or
vere re
f the t
raphic
ms or
vere re
f the t
raphic
ms or
f the t
raphic
ms or
ngiogR (p  0.52). When the analysis was confined to the trials
f
a
0
0
H
y
g
b
s
P
m
1
w
1
1377JACC Vol. 50, No. 14, 2007 Schömig et al.
October 2, 2007:1373–80 SES Versus PESor which individual patient data were available, SES were
ssociated with a HR for stent thrombosis of 0.51 (95% CI
.33 to 0.80, p  0.003). Within the first year, the HR was
.64 (95% CI 0.38 to 1.07, p  0.09); after the first year, the
R was 0.30 (95% CI 0.12 to 0.72, p 0.004). After the first
ear, 7 patients in the SES group and 21 patients in the PES
roup incurred stent thrombosis. Figure 2B shows the proba-
ility curves of stent thrombosis: the 30-month probability of
tent thrombosis was 1.2% in the SES group and 2.6% in the
ES group. As also shown by the curves, the difference was
ore evident after the first 12 months.
In the SES group, 169 patients died as compared with
73 patients in the PES group. Allocation to the SES group
as associated with a HR for death of 0.92 (95% CI 0.74 to
.13, p  0.43) (Fig. 3A). There was no significant
I2 =0%, P (Heterogeneity) = 0.93
P (Overall Effect) = 0.02
Overall
.1 101
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CORPAL 2/331 4/321
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LONG-DES II 1/250 5/250
REALITY 6/684 18/669
SIRTAX 12/503 15/509
TAXI 2/102 2/100
53/4391 82/4304
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Hazard Ratio
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Figure 2 Analysis of Stent Thrombosis
According to the Drug-Eluting Stent Type
(A) Absolute numbers of patients with stent thrombosis and HRs for stent
thrombosis associated with SES versus PES for individual trials and pooled
population. The HRs are shown on a logarithmic scale. The size of the square
is proportional to the weight of the individual studies, measured as the inverse
of the estimated variance of the log HR. (B) Kaplan-Meier curves of stent
thrombosis in the pooled population according to stent type. Abbreviations as
in Figure 1.I2 =6%, P (Heterogeneity) = 0.39
P (Overall Effect) < 0.001
Overall
.1 101
BASKET 22/264 21/281
CORPAL 29/331 38/321
ISAR-DESIRE 19/100 30/100
ISAR-DIABETES 14/125 17/125
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LONG-DES II 6/250 18/250
REALITY 60/684 59/669
SIRTAX 40/503 67/509
TAXI 9/102 4/100
295/4391 380/4304
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No. of events / Total No. of patients
SES group PES group
Favors
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PES
Hazard Ratio
0.74 (0.63, 0.87)
Zhang et al. 14/246 16/203
Cervinka et al. 1/37 3/33
Di Lorenzo et al. 3/90 4/90
Han et al. 9/210 11/206
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Figure 1 Analysis of Reintervention
According to the Drug-Eluting Stent Type
(A) Absolute numbers of patients requiring reintervention and hazard ratios
(HRs) for this end point with sirolimus-eluting stent (SES) versus paclitaxel-elut-
ing stent (PES) for individual trials and pooled population. The HRs are shown
on a logarithmic scale. The size of the square is proportional to the weight of
the individual studies, measured as the inverse of the estimated variance of
the log HR. (B) Kaplan-Meier curves of reintervention in each of the stent
groups for the pooled population. Hazard ratio indicates the HR associated
with the SES. BASKET  Basel Stent Kosten Effektivitäts Trial; CI  confi-
dence interval; CORPAL  Drug-Eluting Stents for Complex Lesions: Random-
ized Rapamycin Versus Paclitaxel trial; ISAR-DESIRE  Intracoronary Stenting
and Angiographic Results: Drug-Eluting Stents for In-Stent Restenosis trial;
ISAR-DIABETES  Intracoronary Stenting and Angiographic Results: Do Diabetic
Patients Derive Similar Benefit From Paclitaxel-Eluting and Sirolimus-Eluting
Stents trial; ISAR-SMART 3  Drug-Eluting Stenting to Abrogate Restenosis in
Small Arteries Trial; LONG DES II  Randomized Comparison of the Efficacy of
Sirolimus-Eluting Stent Versus Paclitaxel-Eluting Stent in the Treatment of Long
Native Coronary Lesions trial; PROSIT  Prospective Randomized Trial of Siroli-
mus- versus Paclitaxel-Eluting Stents for the Treatment of Acute ST-Elevation
Myocardial Infarction; REALITY  Prospective, Randomized, Multi-Center Com-
parison of the Cypher Sirolimus-Eluting and the Taxus Paclitaxel-Eluting Stent
Systems trial; SIRTAX  Sirolimus-Eluting Versus Paclitaxel-Eluting Stents for
Coronary Revascularization trial; SORT OUT II  Prospective, Multicenter,
Large-Scale, Randomized Trial of Paclitaxel- and Sirolimus-Eluting Stents in
“Real-World” Lesions trial; TAXI  Prospective Randomized Comparison
Between Paclitaxel and Sirolimus Stents in the Real World of Interventional
Cardiology trial.
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SES Versus PES October 2, 2007:1373–80eterogeneity across trials (p  0.98). The sensitivity
nalysis yielded HRs that ranged from 0.89 (95% CI 0.72 to
.11) to 0.94 (95% CI 0.75 to 1.16) and were not signifi-
antly different from the overall HR (p  0.85). When the
nalysis was confined to the trials for which individual
atient data were available, SES were associated with a HR
or death of 0.92 (95% CI 0.73 to 1.17, p  0.50). Within
he first year, the HR was 1.02 (95% CI 0.73 to 1.45, p 
.89); after the first year, the HR was 0.84 (95% CI 0.61 to
.16, p  0.29). Figure 3B shows the probability curves of
eath: the 30-month probability of death was 6.0% in the
ES group and 6.3% in the PES group.
Myocardial infarction occurred in 178 patients in the
ES group versus 205 patients in the PES group.
llocation to the SES group was associated with a HR
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P (Overall Effect) = 0.43
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Figure 3 Analysis of Mortality
According to the Drug-Eluting Stent Type
(A) Absolute numbers of patients experiencing death and HRs for death asso-
ciated with SES versus PES for individual trials and pooled population. The
HRs are shown on a logarithmic scale. The size of the square is proportional to
the weight of the individual studies, measured as the inverse of the estimated
variance of the log HR. (B) Kaplan-Meier curves of mortality in each of the
stent groups for the pooled population. Abbreviations as in Figure 1.or MI of 0.84 (95% CI 0.69 to 1.03, p  0.10) (Fig. 4A).here was no significant heterogeneity across trials (p 
.99). The sensitivity analysis yielded HRs that ranged
rom 0.80 (95% CI 0.64 to 0.99) to 0.87 (95% CI 0.69 to
.10) and were not significantly different from the overall
R (p  0.74). When the analysis was confined to the
rials for which individual patient data were available,
ES were associated with a HR for MI of 0.81 (95% CI
.64 to 1.02, p  0.07). Within the first year, the HR was
.91 (95% CI 0.71 to 1.17, p  0.46); after the first year,
he HR was 0.45 (95% CI 0.25 to 0.80, p  0.006). After
he first year, 18 patients in the SES group and 36
atients in the PES group incurred an MI. Figure 4B
hows the probability curves of MI: the 30-month
robability of MI was 5.3% in the SES group and 7.1%
n the PES group. As also shown by the curves, the
ifference became more evident after the first 12 months.
I2 =0%, P (Heterogeneity) = 0.99
P (Overall Effect) = 0.10
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Figure 4 Analysis of Myocardial Infarction
According to the Drug-Eluting Stent Type
(A) Absolute numbers of patients experiencing myocardial infarction associated
with SES versus PES for individual trials and pooled population. The HRs are
shown on a logarithmic scale. The size of the square is proportional to the
weight of the individual studies, measured as the inverse of the estimated vari-
ance of the log HR. (B) Kaplan-Meier curves of myocardial infarction in each of
the stent groups for the pooled population. Abbreviations as in Figure 1.
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October 2, 2007:1373–80 SES Versus PESegarding the composite of death or MI, SES were
ssociated with a HR of 0.86 (95% CI 0.72 to 1.01, p 
.07).
iscussion
his meta-analysis compared long-term clinical outcomes
fter implantation of SES versus PES in a large population
f patients with various clinical presentations of coronary
rtery disease. Compared with PES, SES significantly
educe the risk of reintervention and stent thrombosis
ithout significantly impacting the risk of death or MI.
Three limitations should be acknowledged before com-
enting on the findings of this study. First, we were only
ble to obtain individual patient data from two-thirds of the
rials. Completeness of patient-level data may increase the
ccuracy of the analysis. It is, however, reassuring that the
reatment effects calculated for the entire population are in
ccordance with those obtained when individual patient
ata was analyzed. Second, 10 of the 16 trials included in
his meta-analysis had a protocol-mandated follow-up an-
iography. This may exaggerate the risk of the occuloste-
otic reflex and lead to an increase in the number of
einterventions, although no significant interaction could be
ound between this study design feature and treatment
ffect. In addition, the fact that the difference in the risk of
eintervention between the 2 DES types persisted even
eyond the scheduled time for follow-up angiography (6 to
months) does not support a significant impact of protocol-
andated follow-up angiography on the treatment effect in
avor of the SES observed in this meta-analysis. Third, all
rials were open-label trials due to the impossibility of
linding completely different devices coming from 2 differ-
nt manufacturers. Although all reported events went
hrough a blind adjudication process, these limitations
ight have had an impact on the evaluation of at least 1 of
he events of interest, the reintervention.
Sirolimus-eluting stents and PES are the most widely
sed drug-eluting stents to date. Delayed healing char-
cterized by persistent fibrin deposition, poorer endothe-
ialization, and local hypersensitivity reaction are some of
he mechanisms put forward for the explanation of the
ate occurrence of thrombosis-related events with drug-
luting stents (41). There have been reports that these
henomena are more pronounced with PES than SES, at
east in the presence of overlapping stents (42). We
bserved that patients treated with SES had a 34%
eduction in the hazard of stent thrombosis relative to
atients treated with PES. This finding, coupled with the
act that SES are associated with less late loss than PES
24,25,29,30), does not support the recently reported
ypothesis that a greater late loss may have a protective
ole against stent thrombosis (12). Notably, the risk of
oth stent thrombosis and MI with PES was particularly
igher after the first year. A different susceptibility to
hrombosis after cessation of clopidogrel treatment be-
ween the 2 DES may explain the higher incidence oftent thrombosis with PES. A higher risk of late stent
hrombosis with PES versus SES was also recently
bserved in a registry of a large series of patients (43).
lthough late stent thrombosis was numerically more
requent with PES, this complication was encountered
ith both DES types and requires maximal attention to
mprove long-term safety. These findings may indicate
hat patients who receive drug-eluting stents require a
eriod of dual antiplatelet therapy longer than that
urrently recommended (44); this may be particularly
mportant for patients who receive PES. We must
cknowledge, however, 2 factors that may interfere with
he results of the analysis of stent thrombosis. First, only
ecently there has been a strong interest in finding a
ommon definition of stent thrombosis, which can be
sed universally in all drug-eluting stent trials. Although
his would constitute an important step forward for
uture trials, the value of the retrospective application of
ew definitions for previously conducted trials is not
roven. Second, although the recommended duration of
lopidogrel therapy in each trial was known, we did not
ave information about the actual length of this therapy
nd related compliance for individual patients.
onclusions
he SES are superior to PES in terms of a significant
eduction of the risk of reintervention and stent thrombosis.
he risk of death was not significantly different between the
DES, but there was a trend toward a higher risk of MI
ith PES, especially after the first year from the procedure.
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